Publications

5596 Results

Evaluating the impact of stratification on the power and cross-arm balance of randomized Phase 2 clinical trials

Authors
A Moseley;M LeBlanc;B Freidlin;R Shallis;A Zeidan;D Sallman;H Erba;R Little;M Othus
Journal / Conference
Clinical Trials 2025;0(0). doi:10.1177/17407745241304065
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
MYELOMATCH

Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study

Authors
S El Kababji;N Mitsakakis;E Jonker;A Beltran-Bless;G Pond;L Vandermeer;D Radhakrishnan;L Mosquera;A Paterson;L Shepherd;B Chen;W Barlow;J Gralow;M Savard;C Fesl;D Hlauschek;M Balic;G Rinnerthaler;R Greil;M Gnant;M Clemons;K El Emam;B Eng
Journal / Conference
Journal of Medical Internet Research vol. 27 | e66821
Year
2025
Research Committee(s)
Breast
Study Number(s)
S0307

Health Care Contact Days for Older Adults Enrolled in Cancer Clinical Trials

Authors
A Gupta;C Till;R Vaidya;D Hershman;J Unger
Journal / Conference
JAMA Netw Open. Mar 3;8(3):e250778
Year
2025
Research Committee(s)
Cancer Care Delivery
PMID
PMID40080017
PMC
PMC11907310

Bone biomarkers and subsequent survival in men with hormone sensitive prostate cancer: results from the SWOG S1216 phase III trial of androgen deprivation therapy with or without orteronel

Authors
P Lara;E Mayerson;E Gertz;C Tangen;A Goldkorn;M Van Loan;M Hussain;S Gupta;J Zhang;M Parikh;P Twardowski;D Quinn;N Vogelzang;I Thompson;N Agarwal
Journal / Conference
European Urology Feb;85(2):171-176
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID37085425
PMC
PMC10662935
Study Number(s)
S1216

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

Authors
C Gallois;Q Shi;J Meyers;T Iveson;S Alberts;A De Gramont;A Sobrero;D Haller;E Oki;A Shields;R Goldberg;R Kerr;S Lonardi;G Yothers;C Kelly;I Boukovinas;R Labianca;F Sinicrope;I Souglakos;T Yoshino;J Meyerhardt;T Andre;D Papamichael;J Taieb
Journal / Conference
Journal of Clinical Oncology Jul 1;42(19):2295-2305
Year
2024
Research Committee(s)
Gastrointestinal
PMID
PMID38547438
Study Number(s)
CTSU/C80702

A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML

Authors
G Garcia-Manero;N Podoltsev;M Othus;J Pagel;J Radich;M Fang;D Rizzieri;G Marcucci;SA Strickland;MR Litzow;M Savoie;B Medeiros;M Sekeres;TL Lin;G Uy;BL Powell;JE Kolitz;RA Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;F Appelbaum;HP Erba
Journal / Conference
Leukemia Jan;38(1):58-66
Year
2024
Research Committee(s)
Leukemia
PMID
PMID37935977
Study Number(s)
S1203

Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

Authors
S Lerner;D McConkey;C Tangen;JJ Meeks;T Flaig;X Hua;S Daneshmand;A Alva;MS Lucia;D Theodorescu;A Goldkorn;M Milowsky;W Choi;R Bangs;D Gustafson;M Plets;IM Thompson
Journal / Conference
Clinical Cancer Research Jan 17;30(2):444-449
Year
2024
Research Committee(s)
Genitourinary
PMID
PMID37966367
PMC
PMC10824507
Study Number(s)
S1314

A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia

Authors
S Patel;M Othus;Y Chae;M Dennis;S Gordon;D Mutch;W Samlowski;W Robinson;E Sharon;C Ryan;G Lopez;M Plets;C Blanke;R Kurzrock
Journal / Conference
Clinical Cancer Research Jan 5;30(1):33-38
Year
2024
Research Committee(s)
Early Therapeutics and Rare Cancers
PMID
PMID37882676
PMC
PMC10842092
Study Number(s)
S1609

Predicting clinical outcomes in the S1314-COXEN Trial using a Multimodal Deep Learning Model Integrating Histopathology, Cell Types, and Gene Expression

Authors
B Faltas;Z Bai;M Osman;M Brendel;C Tangen;T Flaig;M Plets;MS Lucia;D Theodorescu;D Gustafson;S Daneshmand;J Meeks;W Choi;C Dinney;O Elemento;S Lerner;D McConkey;F Wang
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), oral
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S1314

PAPMET2 A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200)

Authors
B Maughan;M Plets;Y Ged;C Tangen;U Vaishampayan;S Lerner;S Lerner;I Thompson
Journal / Conference
ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), TIPS, poster
Year
2024
Research Committee(s)
Genitourinary
Study Number(s)
S2200